吸入用布地奈德联合孟鲁司特钠、左西替利嗪治疗6～12岁小儿咳嗽变异性哮喘的临床疗效观察

目的：探讨吸入用布地奈德联合孟鲁司特钠、左西替利嗪治疗小儿咳嗽变异性哮喘的临床疗效。方法：选取80例6～12岁确诊为咳嗽变异性哮喘的患儿作为研究对象，随机分为观察组和对照组，各40例。对照组采取吸入用布地奈德吸入气雾剂吸入治疗及相应的对症支持治疗，观察组在对照组的基础上加用口服孟鲁司特钠及左西替利嗪治疗。通过测定治疗前后炎症因子水平及肺功能指标，并记录总有效率和不良反应发生情况，评价临床疗效。结果：观察组总有效率为100.00%高于对照组的72.50%(P<0.01)。治疗前，2组患儿的炎症因子水平及肺功能指标差异均无统计学意义(P>0.05);治疗后，观察组与对照组IgE、IL-4、IL-13水平均明显低于治疗前(P<0.01),且观察组降低幅度大于对照组(P<0.01),治疗后，观察组和对照组肺功能指标均明显高于治疗前(P<0.01),且观察组升高幅度大于对照组(P<0.01)。观察组的不良反应发生率7.50%与对照组的22.50%差异有统计学意义(P<0.05)。结论：吸入用布地奈德联合孟鲁司特钠、左西替利嗪治疗小儿咳嗽变异性哮喘能够显著...

Clinical curative effect of budesonide inhalation combined with montelukast sodium and levocetirizine on the treatment of 6-12 years old children with cough variant asthma

ObjectiveTo explore the curative effect of budesonide inhalation combined with montelukast sodium and levocetirizine on the treatment of children with cough variant asthma.MethodsA total of 80 children aged 6-12 diagnosed with cough variant asthma were selected as the research objects, and randomly divided into the observation group and the control group, with 40 cases in each group.The control group received budesonide inhalation aerosol inhalation therapy and corresponding supportive treatment, while the observation group received oral montelukast sodium and levocetirizine on the basis of the control group.The clinical efficacy was evaluated by measuring the levels of inflammatory factors and other pulmonary function indicators before and after treatment, and recording the total effective rate and the occurrence of adverse reactions.ResultsThe total effective rate of the observation group was 100.00%, which was higher than 72.50% of the control group (P < 0.01).Before treatment, there was no significant difference in the levels of inflammatory factors and lung function indexes between the two groups (P>0.05).After treatment, the levels of IgE, IL-4 and IL-13 in the observation group and the control group were significantly lower than those before treatment (P < 0.01), and the reduction range in the observation group was greater than that in the control group (P < 0.01).After treatment, the indexes of lung function in the observation group and the control group were significantly higher than those before treatment (P < 0.01), and the increase in the observation group was greater than that in the control group (P < 0.01).The rate of adverse reactions in the observation group occurred was also lower than that of the control group, and the difference was statistically significant (P < 0.05).ConclusionsBudesonide inhalation combined with montelukast sodium and levocetirizine in the treatment of children with cough variant asthma can significantly improve the effective rate and lung function, reduce the levels of inflammatory factors and the incidence of adverse reactions, which is worth promoting in clinical appilcation.